Drug intelligence / Profile preview

Fibrobody miRNA inhibitor conjugate

Development stage: Preclinical
Lead developer: Linxis Biopharmaceuticals
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics

Overview

Fibrobody miRNA inhibitor conjugate is an experimental therapeutic candidate being developed by Linxis Biopharmaceuticals for the treatment of kidney fibrosis. The drug utilizes the company's proprietary Fibrobody platform, which consists of high-affinity nanobodies (antibody fragments) that specifically target Platelet-Derived Growth Factor Receptor Beta (PDGFRB). PDGFRB is a marker that is significantly overexpressed on activated myofibroblasts, the primary cells responsible for the excessive production of extracellular matrix in fibrotic organs. By conjugating a microRNA (miRNA) inhibitor to the Fibrobody, the platform is designed to deliver the genetic payload directly to fibrotic kidney tissue. This targeted approach aims to modulate the fibrotic process at the molecular level while potentially minimizing systemic side effects. The program is currently in the discovery stage of development.

Other names: Fibrobody miRNA inhibitor conjugate (Kidney Fibrosis)

Targets

PDGFRB (Platelet-derived growth factor receptor beta)

Beyond the preview

Go deeper on Fibrobody miRNA inhibitor conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibrobody miRNA inhibitor conjugate.

Explore the full profile